Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 2833

Drug Profile

RG 2833

Alternative Names: RG-FA; RG2833; RGFP-109

Latest Information Update: 22 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Scripps Research Institute
  • Developer Johns Hopkins University; Repligen Corporation
  • Class Small molecules
  • Mechanism of Action HDAC1 protein inhibitors; HDAC3 protein inhibitors; Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Friedreich's ataxia

Highest Development Phases

  • Preclinical Diffuse intrinsic pontine glioma
  • No development reported Friedreich's ataxia

Most Recent Events

  • 11 Apr 2021 Pharmacodynamics data from preclinical trials in Diffuse intrinsic pontine glioma presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
  • 10 Apr 2021 Preclinical trials in Diffuse intrinsic pontine glioma in USA (unspecified route), before April 2021
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Friedreich's ataxia in Italy (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top